Valuation: ACADIA Pharmaceuticals Inc.

Market Cap 4.96B 4.3B 4.01B 3.68B 6.96B 472B 7.03B 47.08B 18.48B 236B 18.64B 18.23B 782B P/E 2026 *
52.2x
P/E 2027 * 36.6x
Enterprise Value 3.99B 3.46B 3.22B 2.96B 5.6B 380B 5.66B 37.88B 14.87B 190B 15B 14.66B 629B EV / Sales 2026 *
3.17x
EV / Sales 2027 * 2.66x
Free-Float
99.67%
Yield 2026 *
-
Yield 2027 * -
1 day+6.08%
1 week+9.34%
Current month+11.33%
1 month+10.90%
3 months+28.86%
6 months+22.76%
Current year+7.82%
1 week 25.34
Extreme 25.345
29.16
1 month 24.23
Extreme 24.232
29.16
Current year 19.89
Extreme 19.89
29.16
1 year 19.69
Extreme 19.69
29.16
3 years 13.4
Extreme 13.4
32.59
5 years 12.24
Extreme 12.24
33.99
10 years 12.24
Extreme 12.24
58.72
Manager TitleAgeSince
Chief Executive Officer 55 19/09/2024
Director of Finance/CFO 52 09/09/2021
Chief Tech/Sci/R&D Officer - 03/08/2025
Director TitleAgeSince
Director/Board Member 68 30/04/2008
Chairman 55 09/06/2016
Director/Board Member 73 24/11/2015
Date Insider Type Main position Quantity % Market Cap.
30/07/26 Sell

Chief Technology Officer

-16,558 0.0097%
06/02/26 Fiscal year

General Counsel

32,838 0.0194%
17/11/25 Fiscal year

Controller/Auditor

19,948 0.0118%
Change 5-day change 1-year change 3-year change Capi.($)
+6.08%+9.34%+21.83%+5.92% 4.96B
+0.90%-2.33%+0.68%+13.87% 48.57B
+1.98%+9.05%+413.94%+532.17% 41.95B
+3.44%-4.65%+28.34%+8.81% 38.85B
+1.40%+0.10%+6.61%+61.93% 37.24B
+2.42%+5.72%+12.38%+44.79% 30.67B
-0.16%-3.11% - - 16.1B
+2.20%+0.48%+34.71%+127.15% 16.41B
+1.25%+1.52%+4.62%+18.26% 13.97B
+4.25%-8.23%-1.49%-35.46% 12.62B
Average +2.38%+0.23%+57.96%+86.38% 26.13B
Weighted average by Cap. +2.00%+0.06%+80.93%+118.02%

Financials

2026 *2027 *
Net sales 1.26B 1.09B 1.02B 936M 1.77B 120B 1.79B 11.96B 4.7B 59.99B 4.74B 4.63B 199B 1.42B 1.23B 1.15B 1.06B 2B 135B 2.02B 13.5B 5.3B 67.72B 5.35B 5.23B 224B
Net income 101M 87.24M 81.32M 74.79M 141M 9.58B 143M 956M 375M 4.79B 378M 370M 15.87B 134M 116M 109M 99.81M 188M 12.78B 191M 1.28B 501M 6.39B 505M 494M 21.18B
Net Debt -970M -840M -783M -720M -1.36B -92.22B -1.37B -9.2B -3.61B -46.14B -3.64B -3.56B -153B -1.18B -1.02B -955M -879M -1.66B -112B -1.68B -11.22B -4.41B -56.29B -4.44B -4.35B -186B
Logo ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.
Employees
797
Date Price Change Volume
05/08/26 US$28.80 +6.08% 4,549,297
04/08/26 US$27.15 +6.01% 2,440,393
03/08/26 US$25.61 -1.01% 1,368,071
31/07/26 US$25.87 -2.56% 1,534,224
30/07/26 US$26.55 +0.80% 1,298,677
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
28.80USD
Average target price
33.25USD
Spread / Average Target
+15.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACAD Stock